NUC-7738 is under clinical development by NuCana and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs for Lymphoma have a 30% phase transition success rate (PTSR) indication ...
CMN-005 is under clinical development by Benecyte and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...
Exposure to the weedkiller Roundup (glyphosate) has been linked to an increased risk of non-Hodgkin's lymphoma.
It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Non-Hodgkin's Lymphoma Research. Learn more about our innovative pipeline today!
SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that it had submitted its ...
Hosted on MSN1mon
FDA ARMAT status for Affimed and Artiva’s lymphoma combo therapyIt offers benefits similar to a breakthrough therapy designation but is specifically tailored for regenerative medicine products ... for Affimed and Artiva’s lymphoma combo therapy" was ...
Stage 4 lymphoma is when cancer has spread to at least one organ outside the lymphatic system, such as the spinal cord, lungs, bones, or liver. It can cause a range of symptoms. It is an advanced ...
The results of a preclinical study by lymphoma researchers at Weill Cornell Medicine suggest that an emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of ...
The global market for intraocular lymphoma therapy is expected to be worth USD 1.2 billion by the year of 2023. The market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results